Accentia BioPharmaceuticals Company Profile

00:32 EST 16th December 2018 | BioPortfolio

Our mission is to identify, develop, and market innovative biopharmaceuticals to fulfill unmet medical needs which alleviate human suffering caused by disease. Accentia BioPharmaceuticals is a vertically-integrated biopharmaceuticals company focused on the acquisition, development and commercialization of late stage specialty pharmaceuticals and biologics for targeted therapeutics. Corporate Background Accentia BioPharmaceuticals, Inc (Nasdaq:ABPI) is a vertically-integrated specialty biopharmaceutical company, formed by the Hopkins Capital Group, LLC and affiliates to acquire late-stage targeted therapeutics and to use patented delivery technologies to enhance the performance of these therapeutics. The Company consists of two wholly-owned subsidiaries, and a majority, controlling interest in a third company. Together, these assets provide for a comprehensive ability to commercialize biopharmaceuticals. Accentia partners with physicians, insurers, and pharmaceutical manufacturers to guide optimal drug development and patient care, both in the United States and in Europe. Accentia BioPharmaceuticals is focused on the commercialization of "targeted" therapeutics in patent-protected drug delivery technologies related to respiratory, oncology and critical care. Targeted therapeutics represent a rapidly growing market in pharmaceuticals, as well as in private equity spending with nearly $700 million already invested to date in 2003. Indeed the genomic revolution now offers the key means to identify targeted therapeutics. Targeted therapeutics may be synthetic chemicals or naturally occurring products called biologics, such as nucleotides, peptides, cytokines, monoclonal antibodies, or cells which restrict their action to specific cellular targets, thereby reducing undesirable collateral damage (i.e. toxicity), while boosting efficacy. As such, their extraordinary safety profiles enhance the likelihood of accelerated access to the market and their performance profiles encourage enthusiastic adoption by specialists dealing with difficult disease states. Accentia BioPharmaceuticals has chosen to accelerate its organic growth through a combination of mergers and acquisitions of companies, product acquisitions, and in-licensing of late-stage development products. Accentia, as a later-stage company with full capabilities from development to specialized distribution and a rich pipeline of products, is well-positioned to become a market leader in the Biopharmaceutical industry.


324 South Hyde Park Ave., Suite 350
United States of America


Phone: (813) 864-2554
Fax: (813) 258-6912

News Articles [173 Associated News Articles listed on BioPortfolio]

NGM Biopharmaceuticals files for IPO

NGM Biopharmaceuticals Inc. filed for its initial public offering on the Nasdaq.

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene's Virus-Based Immunotherapies TG6002 and TG1050 in Greater China

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares Deals give Tasly Biopharmaceuticals full control over Greater China1 development and commercial rights to the...

Akebia Therapeutics to merge with Keryx Biopharmaceuticals

US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to m...

Eiger BioPharmaceuticals completes enrolment in Prevent trial

Eiger BioPharmaceuticals has completed patient enrolment in the Phase ll Prevent trial evaluating the safety and durability of subcutaneous (SC)...Read More... The post Eiger BioPharmaceuticals comple...

Alder BioPharmaceuticals, Inc. (ALDR) to Present at the Canaccord Genuity 38th Annual Growth Conference

Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic ...

Sirona Biochem Receives US$500,000 Payment from Wanbang Biopharmaceuticals

Sirona Biochem (TSXV:SBM) has announced it has received the US$500,0000 payment from Wanbang Biopharmaceuticals for approval by the China and Food Drug Administration for the company’s Phase I c...

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge

Akebia Therapeutics (NASDAQ:AKBA) and Keryx Biopharmaceuticals (NASDAQ:KERX) today announced that the companies signed, and the boards of directors of both companies have unanimously approved, a defin...

Sienna Biopharmaceuticals' acne drug fails two trials

Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its acne treatment did not meet their main goals of reducing inflammatory lesions on patients' skin.

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Thrombin human [Ethicon, Inc]

These highlights do not include all the information needed to use EVITHROM safely and effectively. See full prescribing information for EVITHROM.EVITHROM, Thrombin, Topical (Human)For Topical Use Only...

PubMed Articles [34 Associated PubMed Articles listed on BioPortfolio]

Acknowledgement to Referees.

Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals.

Protein aggregation is a field of increasing importance in the biopharmaceutical industry. Aggregated particles decrease the effectiveness of the drug and are associated with other risks, such as incr...

Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals.

Synthetic biology has been revolutionizing the biopharmaceutical industry from drug discovery, clinical development to the manufacturing of biopharmaceuticals. As one of its most promising areas, gene...

Selective N-terminal acylation of peptides and proteins with a Gly-His tag sequence.

Methods for site-selective chemistry on proteins are in high demand for the synthesis of chemically modified biopharmaceuticals, as well as for applications in chemical biology, biosensors and more. I...

Surface-induced crystallization of pharmaceuticals and biopharmaceuticals: a review.

Despite crystallization wide occurrence in pharmaceutical industry, deep understanding and fine control of the process remain tricky issues. Nevertheless, the successful manufacturing of finished phar...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Nicotine Vaccination and Nicotinic Receptor Occupancy

This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharm...

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infect...

Companies [188 Associated Companies listed on BioPortfolio]

Accentia Biopharmaceuticals, Inc.

Headquartered in Tampa, Florida, Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPIQ”) is committed to making the autoimmune disease therapy, Revimmune™, available to ...

Accentia BioPharmaceuticals

Our mission is to identify, develop, and market innovative biopharmaceuticals to fulfill unmet medical needs which alleviate human suffering caused by disease. Accentia BioPharmaceuticals is a vertic...

Biovest International

Biovest International Inc, is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically-integrated specialty biopharmaceutical company with services to commercialize targeted thera...

Itero Biopharmaceuticals, Inc.

Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...

Bechtel Group Biopharmaceuticals Production

Design, construction, and validation of facilities for production of human biopharmaceuticals utilizing either fermentation or cell culture, facilities maintenance & operation for the virtual organiza...

More Information about "Accentia BioPharmaceuticals" on BioPortfolio

We have published hundreds of Accentia BioPharmaceuticals news stories on BioPortfolio along with dozens of Accentia BioPharmaceuticals Clinical Trials and PubMed Articles about Accentia BioPharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Accentia BioPharmaceuticals Companies in our database. You can also find out about relevant Accentia BioPharmaceuticals Drugs and Medications on this site too.

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Corporate Database Quicklinks

Searches Linking to this Company Record